ClinicalTrials.gg
TerminatedNCT00327197Updated Aug 4, 2017

Assessment Of Disease Pathology And Key Therapeutic Targets In Severe Asthma

A Phase 1 interventional study of Prednisolone and Bronchoscopy in Asthma, sponsored by GlaxoSmithKline. Terminated at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-08-04.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Why this study was terminated
The study was truncated due to the long period of enrollment and the collection of a sufficient amount of data that allowed the scientific objectives to be met

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Aug 2005, registered May 2006).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies testing prednisolone in Asthma — none open to participants now, 1 under way, none of them phase 3. Prednisolone · Asthma.

Enrollment
13th of 15
47 · median 158
Started
2005
with 1 other
Phase 1
Only one
of the 15
Registered
3rd of 15
by date
Lead sponsor
2 of 15
GlaxoSmithKline

Among the 15 studies testing prednisolone in Asthma, this one is the 13th largest by enrollment, is one of 2 that started in 2005, is the only one in phase 1, and was the 3rd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 15 studies testing prednisolone in Asthma is open now. The open studies under Asthma, anywhere →

About prednisolone

Prednisolone: first FDA approval 1955 (METICORTELONE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing prednisolone in Asthma as a file.
02

Study summary

To evaluate and compare the expression and change in expression of key severe asthma targets at baseline in mile to moderate asthmatics vs. severe asthmatic subjects.

To evaluate and compare the airway pathology at baseline and changes in airway pathology in relation to asthma severity.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • bronchoscopy
  • Sputum induction
  • Prednisolone
  • Asthma
  • biomarkers
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of asthma with exclusion of other significant pulmonary disease.
  • between 19-31 kg.m-2.
  • Subjects will be assigned to group 1(mild to moderate) or Group 2 (severe asthmatics) depending on their Lung Function test results.

Exclusion criteria

Exclusion criteria:

  • As a result of medical interview, physical examination or screening investigation the physician responsible considers the subject unfit for the study.
  • History of drug or other allergy, which, in the opinion of the responsible physician, contra-indicates their participation.
  • Subject is female who is pregnant or lactating.
  • Currently or planning to take during the study regular medication (including over-the-counter) except for medication allowed in inclusion criteria.
  • Having participated within 30 days or 5 half-lives, whichever is longer of the first dose in a study using new molecular entity, or the first dose in any other study investigating drugs or having participated within one month of the first dose in a study with invasive procedures.
  • History or current evidence of an upper or lower respiratory infection or symptoms (including common cold) within 2 weeks of baseline assessments.
  • History of abnormal bruising or bleeding.
  • History of alcohol or drug abuse.
  • Doing night-shift work within at least 5 days prior to dosing until completion of the study.
  • Anticoagulants except low dose of Aspirin (80 mg per day) (for bronchoscopy).
  • Beta blockers except for low dose Atenolol (25 mg/day) or Metoprolol (50 mg/day) (for bronchoscopy).
  • Use of Cytochrome P450 inhibitors.
  • History of to any of the following medications: Lidocaine, Fentanyl, Versed, Demerol, Midazolam, Epinephrine, Flumazenil and Naloxone.
  • History of hypersensitivity to bronchodilator (such as Albuterol).

In addition, the following additional exclusion criteria must apply to mild to moderate persistent asthmatics on regular inhaled :

  • Changed asthma medication within the 4 weeks prior to screening.
  • Has had an asthma exacerbation in the previous month.
  • Known sensitivity or allergy to prednisolone.
  • Current use or use within the previous 3 months of oral corticosteroids.
  • Current use of Methotrexate, cyclosporine and PDE inhibitors
  • History of tuberculosis, diabetes mellitus, osteoporosis, severe hypertension, glaucoma , severe affective disorder and peptic ulceration.

In addition, the following additional exclusion criteria must apply to severe persistent asthmatics with clinical controlled asthma symptoms:

  • Changed asthma medication within the 4 weeks prior to screening.
  • Has had an asthma exacerbation in the previous month.
  • sensitivity or allergy to prednisolone.
  • History of tuberculosis, diabetes mellitus, osteoporosis, hypertension, glaucoma, severe affective disorder and peptic ulceration.
  • Current use or use within the previous 4 weeks of oral prednisolone or equivalent of greater than 20mg daily.
  • Current use of Methotrexate, cyclosporin.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Intermittent mild steroid-naïve asthmatic group

    Asymptomatic subjects receiving only beta-agonist inhaler with predicted FEV1 \>=80% and normal peak expiratory flow between attacks will be included.

    Drug: Prednisolone · Procedure: Bronchoscopy

  • Experimental
    Mild to moderate persistent asthmatic group

    Subjects with mild to moderate persistent asthma on low to moderate dose of inhaled corticosteroid (200-500 microgram fluticasone propionate daily or equivalent), an FEV1 \>= 80% predicted (post-bronchodilator), and less than 20% variability in peak expiratory flow.

    Drug: Prednisolone · Procedure: Bronchoscopy

  • Experimental
    Severe asthma group

    Subjects with severe persistent asthma. They will be on either: high inhaled corticosteroid (CS \>=1000 microgram fluticasone daily or equivalent) or on high dose inhaled CS plus oral CS (no more than 20 milligrams predisolone a day). The subjects should have at least one ( if on oral steroids) or two (if only on inhaled steroids) of the following: 1) FEV1\<80% and FEV1/FVC ratio \<70% 2) more than 25% variability in peak expiratory flow 3) daily symptoms ± nocturnal symptoms 4) severe exacerbations of \>= twice a year in at least one of the last two years.

    Drug: Prednisolone · Procedure: Bronchoscopy

  • Placebo comparator
    Healthy subjects group

    Non-asthmatic and non-smokers with FEV1 \> 85% predicted, on no regular medication.

    Procedure: Bronchoscopy

Interventions

  • Subjects will be administered oral prednisolone at a dose of 0.5 mg/kg, up to a maximum of 40 mg per day for 14 days.

  • ProcedureBronchoscopy

    All subjects will undergo bronchoscopy assessments which will involve insertion of a standard bronchoscope.

06

What researchers measure

Primary outcomes

  1. Airway pathology endpoints Target Validation endpoints Biomarker endpoints Clinical endpoints

    biomarkers, vital signs, ECG

    Time frame: Through 2 weeks of Prednisolone dosing

Secondary outcomes

  1. Expression of airway and systemic biomarkers. Relationship between changes in target expression and clinical measures of disease activity. Relationship between steady state plasma exposure of prednisolone and pharmacodynamic biomarkers.

    biomarkers

    Time frame: Through 2 weeks of prednisolone dosing.

07

Study locations

1 site
  • GSK Investigational Site
    Leicester, Leicestershire LE3 9QP, United Kingdom
08

References and documents

Publications

  • Siddiqui S, Shikotra A, Richardson M, Doran E, Choy D, Bell A, Austin CD, Eastham-Anderson J, Hargadon B, Arron JR, Wardlaw A, Brightling CE, Heaney LG, Bradding P. Airway pathological heterogeneity in asthma: Visualization of disease microclusters using topological data analysis. J Allergy Clin Immunol. 2018 Nov;142(5):1457-1468. doi: 10.1016/j.jaci.2017.12.982. Epub 2018 Mar 14. PubMed 29550052 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2005 to primary completion in Jun 2011, 70 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2006
First posted
May 18, 2006
StartActual
Aug 2, 2005
Primary completionActual
Jun 6, 2011
CompletionActual
Jun 6, 2011
Last update
Aug 4, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00327197
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 18, 2006
Start date
Aug 2, 2005
Primary completion
Jun 6, 2011
Completion
Jun 6, 2011
Last update
Aug 4, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prednisolone

Start the discussion